TNFRSF17 and plasma cell myeloma: Notably, across these lines we detected almost all of the major immunotherapy targets in myeloma, as well as canonical flow cytometry markers for plasma cells7,13: BCMA, CD138/SDC1, CD38, CD56, SLAMF7/CS-1, CD46, Integrin-b7 (ITGB7), CD74/HLA-DR, TACI, CD48/SLAMF2, and LY9/CD229 (Fig. 1C; Supplementary Data 1).